Immunotherapy drug nivolumab tested against recurrent brain tumors
NCT ID NCT03557359
First seen Nov 03, 2025 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This phase 2 trial tested the drug nivolumab (Opdivo) in 35 adults with recurrent or progressive IDH mutant gliomas (a type of brain tumor) that had been previously treated with chemotherapy. The main goal was to see if the drug could shrink tumors. The study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Miami Cancer Center
Miami, Florida, 33176, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo)
What this could lead to
If it works, this could point toward a treatment option for people with recurrent IDH mutant gliomas that have not responded to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 35 participants and no comparison group, so results may not be conclusive. Nivolumab can cause immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.